GSK Brings Precision Oncology Drugs Jemperli and Zejula to India
Mumbai – August 25, 2025 — GSK India has entered the oncology space in the country with the launch...
Advertisement
NATCO Launches Generic Bosentan Tablets for Oral Suspension in the U.S. with 180-Day Exclusivity
Hyderabad, India, August 20, 2025 – NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) today announced the launch of...
SmartLabs and Sonrai Form Exclusive AI Partnership to Accelerate Precision Medicine and Scientific Discovery
SmartLabs and Sonrai Analytics today announced a global strategic alliance to integrate Sonrai’s next-generation AI platform, Sonrai Discovery, into...
Stramsen Biotech Submits Pre-IND Package to FDA for SBX1977, Seeks Phase 2 Pathway in Wound Care
Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to...
D3 Bio Wins FDA Breakthrough and Orphan Drug Designations for D3S-001 in KRAS G12C-Mutated Cancers
Shanghai – August 28, 2025 — D3 Bio, Inc., a clinical-stage precision oncology company, announced that the U.S. Food...
FDA Approves Updated 2025–2026 COVID-19 Vaccines from Pfizer, Moderna, and Novavax
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
FDA Ends Broad Emergency Authorization, Approves Updated COVID-19 Vaccines
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
RNAConnect® Launches UltraMarathonRT® Kit to Transform Short-Read RNA Sequencing
RNAConnect today announced the commercial launch of the UltraMarathonRT® (uMRT) cDNA Synthesis and Amplification Kit, a next-generation tool designed...
American Regent Debuts Gvoke VialDx, Innovative Glucagon for Radiology
SHIRLEY, N.Y., August 27, 2025 — American Regent, Inc.® has announced the commercial launch of Gvoke VialDx™ (glucagon injection),...
Glycovax Pharma to Develop Pseudomonas Vaccine After NRC License Approval
MONTREAL, Aug. 18, 2025 — Glycovax Pharma has secured a license from the National Research Council of Canada (NRC)...
Advertisement
